Continuous Glucose Monitoring AI

Abbott's FreeStyle Libre 3 and Dexcom G7 CGM systems integrated AI prediction algorithms that could forecast blood glucose levels 60-120 minutes into the future with clinical-grade accuracy, enabling proactive insulin dosing decisions for the 537 million people with diabetes worldwide. The closed-loop artificial pancreas systems combining CGM + AI + insulin pump achieved near-normal glucose control in 90% of Type 1 diabetic users in real-world studies.